In Australia , the 750mcg's rhPTH(1-34) solution is presently accessible through specialty pharmacies , typically subject to special authorization . Market uptake of this stronger formulation has been moderately limited due to its price , stringent patient selection , and the continued need for patient education regarding its administration and pot